Roche on Track for Steady Sales Growth Next Year

Dow Jones11-04

1233 GMT - Roche Holding is on track to deliver steady sales growth next year, as all eyes are on the launch of its new breast-cancer drug giredestrant, Berenberg analysts say in a research note. Berenberg expects the Swiss drugmaker's sales to grow 6% at constant exchange rates in 2027. For 2026, the company has guided for sales growth excluding currency movements in the mid-single-digit percentage range. Roche is comfortable with current estimates that put giredestrant's 2027 sales at between 500 million and 600 million Swiss francs, the analysts say, citing a call with the company's CFO Alan Hippe. The main headwinds Roche will face in 2027 are sales erosions for its Actemra and Perjeta drugs due to lower-priced biosimilar versions, Berenberg says. Shares rise 0.2%.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment